Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6090
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Konkle, Barbara A. | - |
dc.contributor.author | Oldenburg, Johannes | - |
dc.contributor.author | Pasi, John | - |
dc.contributor.author | Kulkarni, Roshni | - |
dc.contributor.author | Nolan, Beatrice | - |
dc.contributor.author | Mahlangu, Johnny | - |
dc.contributor.author | Young, Guy | - |
dc.contributor.author | Brown, Simon A. | - |
dc.contributor.author | Pabinger, Ingrid | - |
dc.contributor.author | Shapiro, Amy | - |
dc.contributor.author | Négrier, Claude | - |
dc.contributor.author | Blanchette, Victor | - |
dc.contributor.author | Ragni, Margaret V. | - |
dc.contributor.author | Dumont, Jennifer | - |
dc.contributor.author | Lethagen, Stefan | - |
dc.date.accessioned | 2024-06-20T00:30:17Z | - |
dc.date.available | 2024-06-20T00:30:17Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Research and practice in thrombosis and haemostasis, 2023 (7) 6 p.102180 | en |
dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6090 | - |
dc.description.abstract | Background: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed control, including joint health maintenance.; Objectives: To assess long-term efficacy and safety of rFVIIIFc prophylaxis in severe hemophilia A in phase 3 pivotal (A-LONG/Kids A-LONG) and extension (ASPIRE) studies.; Methods: Longitudinal analysis included pooled data from A-LONG/Kids A-LONG and ASPIRE. Subgroup analyses investigated outcomes in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score and target joints in subjects with 4 to 5 years follow-up on individualized prophylaxis (IP), and those with the highest annualized bleeding rate (ABR) quartile during Year 1 of IP.; Results: Overall, rFVIIIFc consumption remained stable and low ABRs were maintained, with a median treatment duration of 4.2/3.4 years in subjects from A-LONG/Kids A-LONG, respectively. Median overall ABR also remained low (1.0-2.0) in subjects on IP for 4 to 5 years. Sustained improvements in modified Hemophilia Joint Health Score or Hemophilia Joint Health Score were demonstrated over a median follow-up of 3.7 years. In subjects from A-LONG/Kids A-LONG, 99.6% ( n = 234)/100% ( n = 9) of evaluable baseline target joints were resolved, with no recurrence in 95%/100% of target joints. In IP subjects within the highest ABR quartile in Year 1, continued improvements were observed over a median follow-up of 4.3 years in ABR and joint health, without increased factor consumption. No inhibitors or treatment-related serious adverse events were reported.; Conclusion: Previously treated subjects of all ages receiving long-term prophylaxis with rFVIIIFc had sustained clinical benefits, including improved joint health and low ABR. (© 2023 The Author(s).) | - |
dc.title | Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults | - |
dc.identifier.doi | 10.1016/j.rpth.2023.102180 | - |
dc.relation.url | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=37753224&site=ehost-live | - |
dc.identifier.journaltitle | Research and practice in thrombosis and haemostasis | - |
dc.identifier.risid | 4193 | - |
dc.description.pages | 102180 | - |
dc.description.volume | 7 | - |
dc.description.issue | 6 | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
Appears in Sites: | Children's Health Queensland Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.